RecruitingPhase 3NCT07037433
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
Sponsor: Amgen
Provo, UT · West Jordan, UT · +138 more sites